Sign In
Buy PACB
$1.15
-0.0350 (-2.95%)
At Close: Aug 10, 2026
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
03:31am, Friday, 08'th May 2026
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
07:01pm, Thursday, 07'th May 2026
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago
PacBio Announces First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
12:50pm, Tuesday, 05'th May 2026
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
Critical Review: Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB)
01:12am, Monday, 27'th Apr 2026
Autonomix Medical (NASDAQ: AMIX - Get Free Report) and Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) are both small-cap medical companies, but which is the better investment? We w
Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors
07:16pm, Wednesday, 22'nd Apr 2026
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.71, marking a -1.16% move from the previous day.
PacBio & Lucid Genomics Partner to Boost Data Analysis, Stock Up
11:56am, Wednesday, 22'nd Apr 2026
PACB stock gains on Lucid Genomics deal, boosting HiFi data analysis and simplifying workflows to speed insights and expand adoption.
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
09:05am, Tuesday, 21'st Apr 2026
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem Expands access to streamlined genomic data analysis across the PacBio partner ecosystem
PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing
11:10am, Friday, 17'th Apr 2026
PACB stock rises after unveiling a new FFPE workflow with Covaris, boosting HiFi sequencing accuracy and unlocking insights from archived tumor samples.
PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
04:05pm, Thursday, 16'th Apr 2026
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thur
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
07:16pm, Wednesday, 15'th Apr 2026
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.6, marking a +1.91% move from the previous day.
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
09:05am, Wednesday, 15'th Apr 2026
New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research New extraction-to-library prep workflow
Three Best Genomics Stocks for Your Portfolio in 2026
11:20am, Monday, 13'th Apr 2026
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
07:16pm, Tuesday, 07'th Apr 2026
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.44, moving +1.41% from the previous trading session.
Financial Analysis: Pacific Biosciences of California (NASDAQ:PACB) versus DexCom (NASDAQ:DXCM)
01:40am, Tuesday, 07'th Apr 2026
Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two
